At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 258 enrolled
Drug / intervention
Revefenacin 175 mcg in 3 ML Inhalation Solution +1 moredrug
Likely dose
Revefenacin 175 mcg in 3 ML Inhalation Solutionfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study of Nebulized Revefenacin Inhalation Solution in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD).
In Brief
A Phase 3 clinical trial evaluating Revefenacin 175 mcg in 3 ML Inhalation Solution and Placebo inhalation solution QD for COPD. Completed, enrolled 258 participants across 35 sites.
Detailed Summary
This study is a phase III clinical study to assess the efficacy and safety of Revefenacin inhalation solution 175 mcg administered once daily via nebulization for 12 weeks compared to placebo in a population of Chinese subjects with moderate to very severe COPD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOPD
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedSep 2021
Enrollment StartNov 2021
Primary CompletionJul 2023
TodayJul 2026
First PostedSep 16, 2021
Enrollment StartNov 10, 2021
Primary CompletionJul 26, 2023
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 4.8 years ago
Interventions
Revefenacin 175 mcg in 3 ML Inhalation Solutiondrug
Revefenacin
Placebo inhalation solution QDdrug
Placebo